GSK receives FDA approval for oral antibiotic to treat UTIs
Tweet
Share
E-mail
Get Alerts GSK Hot Sheet
Price: $50.76 -0.04%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 4.8%
Revenue Growth %: +37.9%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 4.8%
Revenue Growth %: +37.9%
Join SI Premium – FREE
The U.S. Food and Drug Administration has approved GSK's (NYSE: GSK) oral antibiotic for the treatment of complicated urinary tract infections, according to a statement from the regulator.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
- Netflix raises $1 billion in senior notes due 2036
- Starfighters (FJET) files for 5.22M share offering by selling stockholders
Create E-mail Alert Related Categories
Corporate News, FDARelated Entities
Maynard Um, Mark Zuckerberg, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
